Skip to main content

Table 1 Baseline demographic, clinical, and laboratory data for enrolled patients with CHA and HCV infection (n=21)

From: Microelimination of hepatitis C in patients with chronic hemolytic anemias: a single-center experience

Characteristics Frequency (%)/mean±SD
Gender  
 Male 10 (47.6%)
 Female 11 (52.4%)
Age (years) 18–62 (median 33)
BMI (kg/m2) 24.4±3.67
Treatment status  
 Naïve 20 (95.2%)
 Experienced 1 (4.8%)
Treatment duration  
 12 weeks 8 (38.1%)
 24 weeks 13 (61.9%)
Diagnosis  
 β-Thalassemia major 12 (57.1%)
 β-Thalassemia intermedia 6 (28.6%)
 β-Thalassemia minor 1 (4.8%)
 Sickle cell anemia 1 (4.8%)
 Hemolytic anemia due to cryoglobulins and cold agglutinins 1 (4.8%)
Child-Pugh score  
 A 13 (61.9%)
 B 8 (38.1%)
Blood transfusion  
 Regular 18 (85.7%)
 Sporadic 2 (9.5%)
 No 1 (4.8%)
Iron chelators  
 No 9 (42.86%)
 Deferoxamine 4 (19.05%)
 Deferiprone 3 (14.28%)
 Deferasirox 5 (23.81%)